Pharsight

Drugs that contain Selpercatinib

1. Retevmo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 8, 2025
Orphan Drug Exclusivity (ODE) Sep 21, 2029

NCE-1 date: 2024-05-08

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with...

Dosage: CAPSULE;ORAL

More Information on Dosage

RETEVMO family patents

Family Patents